Increases of greater than 50 % at week 60 ( primary end point ) were achieved in 39 patients ( 81 % ) and 32 ( 67 % ) in the IV and SC IL-2 arms , respectively , compared with 13 ( 29 % ) in the HAART arm ( P < .001 for both ) .
